about
Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins.Leukemia associated antigens: their dual role as biomarkers and immunotherapeutic targets for acute myeloid leukemiaIdentification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors.Lentivirus-mediated bcl-2 gene therapy improves function and structure of chemotherapy-damaged ovaries in wistar rats.Regulators of apoptosis: suitable targets for immune therapy of cancer.Design and development of synthetic peptide vaccines: past, present and future.Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia.Cancer treatment: the combination of vaccination with other therapies.The functioning antigens: beyond just as the immunological targets.Peptide vaccination against multiple myeloma using peptides derived from anti-apoptotic proteins: a phase I trial.Therapeutic cancer vaccines in combination with conventional therapy.Immunotherapy of chronic myeloid leukemia: present state and future prospects.The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens.Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia.High frequency of T cells specific for cryptic epitopes in melanoma patientsCharacterization of ex vivo expanded tumor infiltrating lymphocytes from patients with malignant melanoma for clinical application.HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer.Spontaneous presence of FOXO3-specific T cells in cancer patients.Characterization and comparison of 'standard' and 'young' tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution.Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients.
P2860
Q33345150-ADD0E0B7-4242-40CC-987D-EB501956BBEDQ33491557-7BC6265A-9795-4617-8AA1-5BCE4DE32A78Q34508082-1CAE1702-9D95-4703-A28A-CCE50BFA6620Q34545919-238A391A-868A-402A-8600-10A133FC68BCQ36111911-2FD66CDA-2B62-4E16-B1FA-21B280215795Q36899093-6B762C98-AD45-40AF-B288-C757FE62DBF5Q37088532-447DE99B-FC2C-44AC-A9F4-E95DCB2C2B68Q37089001-46E5953E-AA0E-4F5A-9F8A-7293A0DB9C85Q37483795-267F5693-DEA5-4DA4-A4EE-5FAB88079DA8Q37574649-ACA8FE8E-9343-4B36-A408-C512B358EC7AQ37771267-83A18C76-20AD-44AB-8747-2ED42964A950Q37773256-E37EB198-2F46-4246-871D-E37F0629BB98Q37838167-712AC836-BAD0-4F2C-9B0B-603FFC8CFC10Q38015123-99992C68-F414-4995-87DA-E623D9775F16Q42141424-9B1FF4ED-5D1A-4FA1-8678-9EFF4E049CB7Q42798738-1C59AB93-F2A0-45DB-A940-57511E16E551Q43166550-14A4F0C4-F54A-47B4-8550-421E717DDA02Q43196241-32E80E13-F9D9-4588-A6B5-8FBE9D182269Q50554742-E8E04010-9EB4-4770-8C96-7F6D6CBE5945Q53538160-B115EBA7-58C7-4ABB-8881-BDE41F2A881C
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Immunogenicity of Bcl-2 in patients with cancer.
@en
type
label
Immunogenicity of Bcl-2 in patients with cancer.
@en
prefLabel
Immunogenicity of Bcl-2 in patients with cancer.
@en
P2093
P50
P1433
P1476
Immunogenicity of Bcl-2 in patients with cancer.
@en
P2093
Eva Balslev
Jürgen C Becker
Ove Juul Nielsen
Pia Kvistborg
Sine Reker
P304
P356
10.1182/BLOOD-2004-07-2548
P407
P577
2004-09-14T00:00:00Z